Heart failure & cardiomyopathies
Improvement in Left Atrial Strain Following Ferric Carboxymaltose in Heart Failure: An Analysis of the Myocardial-IRON Trial
Primary result · LA-LSResult — go to the resultDifference - ∆ 3.55 %Authors' conclusion
In patients with stable HF, LVEF < 50%, and ID, treatment with FCM was associated with short-term improvements in LA-LS assessed by CMR-FT.
Study context
- Population
- Ambulatory patients with heart failure (HF), left ventricular ejection fraction (LVEF) < 50% and iron deficiency
- Participants
- 53 patients
- Comparison
- Ferric carboxymaltose (FCM) vs placebo
- Primary endpoint
- Change in left atrium (LA) longitudinal strain (LA-LS) by CMR feature tracking
- Follow-up
- 30 days
Methodological detailspost hoc subanalysis, double-blind, placebo-controlled
- Post hoc subanalysis
- Double-blind
- Placebo-controlled
Primary result
LA-LS
Difference
- ∆ 3.55 %
P < 0.001
By group
FCM
−12.0
± 0.5
Placebo
−8.5
± 0.6
As reported in the abstract
Original publication
Improvement in Left Atrial Strain Following Ferric Carboxymaltose in Heart Failure: An Analysis of the Myocardial-IRON Trial. ESC Heart Fail. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →